Bakhtiari Hadi, Palizban Abbas Ali, Khanahmad Hossein, Mofid Mohammad Reza
Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I. R. Iran.
Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I. R. Iran.
Res Pharm Sci. 2020 May 11;15(2):107-122. doi: 10.4103/1735-5362.283811. eCollection 2020 Apr.
Cancer is typically associated with abnormal production of various tumor-specific molecules known as tumor markers. Probing these markers by utilizing efficient approaches could be beneficial for cancer diagnosis. The current widely-used biorecognition probes, antibodies, suffer from some undeniable shortcomings. Fortunately, novel oligonucleotide-based molecular probes named aptamers are being emerged as alternative detection tools with distinctive advantages compared to antibodies. All of the existing strategies in cancer diagnostics, including those of detection, can potentially implement aptamers as the detecting moiety. Several studies have been performed in the field of cancer detection over the last decade. In order to direct future studies, it is necessary to comprehensively summarize and review the current status of the field. Most previous studies involve only a few cancer diagnostic strategies. Here, we thoroughly review recent significant advances on the applications of aptamer in various detection strategies. Furthermore, we will discuss the status of diagnostic aptamers in clinical trials.
癌症通常与各种被称为肿瘤标志物的肿瘤特异性分子的异常产生有关。利用有效的方法探测这些标志物可能有助于癌症诊断。目前广泛使用的生物识别探针——抗体,存在一些不可否认的缺点。幸运的是,一种名为适配体的新型基于寡核苷酸的分子探针正在作为一种与抗体相比具有独特优势的替代检测工具而出现。癌症诊断中的所有现有策略,包括检测策略,都有可能将适配体用作检测部分。在过去十年中,该领域已经进行了几项研究。为了指导未来的研究,有必要全面总结和回顾该领域的现状。以前的大多数研究只涉及少数癌症诊断策略。在这里,我们全面回顾了适配体在各种检测策略应用方面的最新重大进展。此外,我们将讨论诊断适配体在临床试验中的现状。